Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
this could be a unique opportunity to buy today. 50% under cash value and then with a new future after the R / M. Anything but a big bounce would be very surprising to me.
Anyone contacted EDGE IR? This pps is so low.
i not wonder if new company owners load all this cheap shares. New company with new pipeline and new future. R/M updates and strategic outlook could trigger the turn around. sellers looks done. EDGE cash value alone 100% higher like current share price
yes, looks like old EDGE insiders sold out and going away. but the R/M is huge. not wonder if tomorrow start a first strong bounce. EDGE extremly undervalued now.
How is possible to trade at this level? Seems crazy. Only cash is 1$ per share....
You bought 30,000 shares of EDGE@ $1.20?
Goony goo goo...blahblah blah
Rofl -16% and like i said ( and warned) yesterday, EDGE shareholders only paltry 30% of the new co.
How can one possibly still be in this stock, considering how much it has fallen on "merger news"??
Wake up
The Reverse Merger is a big Deal for EDGE and u think EDGE is a 500% 1000% ticket. maybe insiders from old Company sold out all shares and going away. thats maybe the reason for the down yesterday and today. but this don't change anything on the fact thats the R/M is huge for EDGE. new company new pipeline New future. The Merger Updates and the outlook from new company will send EDGE up. the selling guys are out now. sells dry out last 60 min. could be start anytime from here. looks like we have build a bottom. EDGE now ready. Insiders out and new strong hands load on R/M. I am also red now. but i hold my shares. the R/M is great News for the new future and i bet big rising share price. my opinion.
LMAO only down 15k on this, but looking at your track record that's like a win for you!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=139655797
Edge Therapeutics, Privately Held PDS Biotech Announce Reverse Merger
by Shanthi Rexalinea day ago
EDGE
Penny stock Edge Therapeutics Inc (NASDAQ: EDGE) is seeing strong buying interest Monday following the announcement of a merger agreement.
The stock was trading up by 4.31 percent to 73 cents at the time of publication.
What Happened
Edge Therapeutics announced its intention to merge with the privately held, clinical-stage cancer immunotherapy company PDS Biotechnology Corp. The boards of both companies approved the proposed transaction, the companies said in a joint press release.
The reverse merger deal is structured as a stock-for-stock transaction in which all PDS shares would be converted into Edge common stock, with the exchange ratio suggesting that immediately following the merger, PDS shareholders will own about 70 percent of the combined company and existing Edge shareholders will hold the remainder.
A reverse merger deal is a transaction in which an active private company merges with a dormant public company in a bid to go public without having to go through the arduous route of a traditional initial public offering.
Edge announced a comprehensive review of strategic alternatives in April in a bid to maximize shareholder value. The decision followed a failed late-stage trial of its aneurysmal subarachnoid hemorrhages treatment candidate, which subsequently forced the company to announce layoffs.
Why It's Important
Edge sees the merger as facilitating the creation of a publicly traded immuno-oncology company that develops novel products to treat early- and late-stage cancer.
PDS Biotech's lead candidate PDS101 has demonstrated immunotherapeutic anti-cancer activity and a favorable safety profile in early stage cervical cancer in a Phase 1/2 clinical trial.
"We expect that the combined company will have the financial resources and experienced leadership to accomplish our key near-term objectives: first, to initiate multiple late-stage clinical studies for our lead product candidate PDS0101; and second, to further advance our preclinical programs toward the clinic," PDS CEO Frank Bedu-Addo said in a statement.
What's Next
The deal is expected to close in the first quarter of 2019.
Following the consummation of the deal, the merged entity will function under the name PDS Biotechnology Corp., with the shares of the combined company to be listed on the Nasdaq under a new ticker symbol to be announced at a later date.
On the pipeline front, the combined company plans to initiate Phase 2b/3 clinical trials of PDS101 in HPV-associated cancers.
EDGE -3.6% on merger news
Answer the question
The Pos Scam crashed to a New 52-week low $0.6504 today after the so-called Merger "Good News", LOL!
Who are those very stupid buyers which paid $1.02 ~ $0.68 to buy EDGE? Only $0.6799 ~ $0.6504 buyers could make some small gains!
Very soon it will create A Series Of New 52-week lows till it hits the Real Bottom $0.50... Sell ASAP!
Ok so closing near the day low is positive for you?
And this was your expected news, a merger
EDGE shareholders will only own 30% of the new entity.
The new entity will utilize EDGE's remaining cash on hand.
Why else do you think this thing turned red on that merger news today?
$3.5 Million volume. real money load today.
EDGE has announced something big. It's not about 30% + or 1% - of today. It's about what the merger brings to EDGE and the shareholders. and I'm not here for $ 1 but for $ 5 $ 6 next. The Merger Announcement is the beginning of a new story. New pipeline starts.
Speak English
Actually it's not.
EDGE share price has been Trading on their cash on hand value.
Today's news was simply that a merger is occurring and shareholders are only going to own 30% of the company
Why do you guys think this is selling off now?
Wake up
EDGE is now RED on the session, for the very reason I stated
PDS company with a growing pipeline of next generation cancer immunotherapies based on the proprietary, multi-functional Versamune
Edge Therapeutics, Inc. (Nasdaq: EDGE) and PDS Biotechnology Corporation, a privately-held, clinical-stage cancer immunotherapy company, announced today that their respective boards of directors have approved a definitive merger agreement. The merger is expected to create a combined company with a growing pipeline of next generation cancer immunotherapies based on the proprietary, multi-functional Versamune® technology platform, and sufficient cash to fund operations into 2020.
“We believe that the proposed merger of PDS Biotechnology and Edge Therapeutics will create a combined company that can generate shareholder value through our proprietary Versamune® platform and a promising pipeline of next generation immunotherapies targeting several cancer markets including the multi-billion-dollar HPV-induced cancer market,” said Frank K. Bedu-Addo, Ph.D., Co-Founder, President and Chief Executive Officer of PDS. “We expect that the combined company will have the financial resources and experienced leadership to accomplish our key near-term objectives: first, to initiate multiple late-stage clinical studies for our lead product candidate PDS0101; and second, to further advance our preclinical programs toward the clinic.”
EDGE THIS NEWS IS HUGE. I'm loading the boat here
EDGE is up 4% on this news
Didn't you actually read the wording of the news?
EDGE shareholder percentage of new company is only 30%
EDGE R/M News out. Very big time coming now. $5 $6 my target for EDGE. looking forward. fantastic day for all EDGE Investors. Company going forward into a new future. new revulation coming now. just a great News. next days new company maybe start outlook. can't wait for it.
Because you need to read the details of this reverse merger. EDGE shareholders are only benefiting by receiving 30% stake in the company
Contrary to popular belief, I cannot be in possession of every sock
Hiding?
Im up $26,000 on GTHP today so I'm monitoring that.
EDGE news, did you bother to read it?
EDGE shareholders will only own approximately 30% of the new company.
Aren't you wondering why the stock isn't moving up?
I'm not missing anything here.
EDGE start into a New future. today was a good boarding day for coming time with EDGE. looks great for me
where r u hiding smiling b ? news!!
EDGE R/M not any one day wonder news. thats a monsta News for this shell biotech company. new future now! with current market cap EDGE is maybe cheapes NASDAQ biotech company. not for long time imho. going into. for me now save $5 $6 turn next days and weeks. Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Intraday Stock Chart
Today : Monday 26 November 2018
Click Here for more EDGE THERAPEUTICS, INC. Charts.
-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer-
Edge Therapeutics, Inc. (Nasdaq: EDGE) and PDS Biotechnology Corporation, a privately-held, clinical-stage cancer immunotherapy company, announced today that their respective boards of directors have approved a definitive merger agreement. The merger is expected to create a combined company with a growing pipeline of next generation cancer immunotherapies based on the proprietary, multi-functional Versamune® technology platform, and sufficient cash to fund operations into 2020.
“We believe that the proposed merger of PDS Biotechnology and Edge Therapeutics will create a combined company that can generate shareholder value through our proprietary Versamune® platform and a promising pipeline of next generation immunotherapies targeting several cancer markets including the multi-billion-dollar HPV-induced cancer market,” said Frank K. Bedu-Addo, Ph.D., Co-Founder, President and Chief Executive Officer of PDS. “We expect that the combined company will have the financial resources and experienced leadership to accomplish our key near-term objectives: first, to initiate multiple late-stage clinical studies for our lead product candidate PDS0101; and second, to further advance our preclinical programs toward the clinic.”
“Since announcing our plans to seek strategic alternatives for Edge Therapeutics, our priority has been to identify a merger candidate that we believe has the potential to continue our mission to help patients and to provide meaningful value to our stockholders," said Brian A. Leuthner, Edge’s President and Chief Executive Officer. “Following a rigorous evaluation and diligence process, the Edge Board of Directors has concluded that a merger with PDS Biotechnology, with a clinical-stage product candidate that has demonstrated the potential in patients to address important limitations of current immuno-oncology approaches, a growing development pipeline, and a novel next generation technology, offers an excellent opportunity to create such value. We believe that PDS represents an attractive merger partner for Edge as PDS prepares to advance multiple late-stage clinical programs through key milestones in 2019 and beyond.”
Versamune® Platform
PDS Biotechnology’s Versamune® platform is based on novel and proprietary synthetic cationic lipids, which promote critical intra-cellular delivery of tumor-related antigens and activate important immunologic signaling pathways that induce effective priming and proliferation of critical populations of killer T-cells able specifically to attack and kill cancerous cells. Versamune® induces the activation of type I interferons and associated chemokines resulting in a potentially powerful and targeted immune response against cancer cells. In addition, in preclinical studies, Versamune® has been shown to overcome important immuno-suppressive cells that exist within the tumor to protect the tumor from T-cell attack.
Growing Product Pipeline
PDS Biotechnology is developing PDS0101 for the treatment of multiple human papilloma virus (HPV)-induced cancers, including cervical, anal and head and neck cancers. PDS Biotechnology plans to initiate multiple Phase 2/3 clinical trials for PDS0101 in HPV-associated cancers.
In a Phase 1/2a dose-escalating study of PDS0101, results confirmed preclinical projections of high levels of active HPV-specific killer T-cells (CD8+) and memory T-cell induction. In addition, T-cell responses were independent of patient genetic/HLA sub-types. In the study, no dose-limiting toxicities were observed.
In addition to PDS0101, PDS Biotechnology’s pipeline includes multiple preclinical programs developing Versamune®-based cancer immunotherapies in combination with checkpoint inhibitors for various late-stage cancers.
why retailers selling .80-.7 this morning on this news???i scratch my head
multipler. With this merger EDGE back in Business with new future. great time ahead now.
Merger is good news. Should be above $1, not almost at the same pps as before merger.
pps spike to 1 in premarket ...i think it will go up further instead tank...why? good news?
been holding hoping for merger and now it happens....pps not spike according to our plan...why? damm good news pps not moving
Market seems not to care about the merger.
i will take profit by $5 $6. EDGE with aMerger!! Thats absolute turn around news. New revulation start now. just warm up so far. New future for EDGE. great time start now. I bet we will see now great news flow after this Merger.
Needs to be above $1 for now.
New revulation ahead now for EDGE. Multi day run start i think. This Merger is crazy big for EDGE. very undervaled now. I think we trading $5 $6 very fast.
Yep looks good. $15 stock not to long ago
$5 $6 turn start now. SQUEEZE 1.0 ahead today. EDGE now with new future with this huge Merger. thats a absolute winner stock now imho. new future!!! my next BCRX EBIO 1000% Biotech bouner i bet.. glad to load here. sound fantastic.
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1509
|
Created
|
09/30/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |